Paper42226175
GGT-triggered self-immolative dexamethasone-oligopeptide prodrug nanoparticles ameliorate hepatic fibrosis via dual anti-inflammatory/immunomodulatory pathways with minimized systemic toxicity.
Zhu Z and 12 others. J Nanobiotechnology, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. GGT-triggered self-immolative dexamethasone-oligopeptide prodrug nanoparticles ameliorate hepatic fibrosis via dual anti-inflammatory/immunomodulatory pathways with minimized systemic toxicity. Papers, record 42226175. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42226175
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- GGT-triggered self-immolative dexamethasone-oligopeptide prodrug nanoparticles ameliorate hepatic fibrosis via dual anti-inflammatory/immunomodulatory pathways with minimized systemic toxicity.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Prodrugs | Major topic |
| Nanoparticles | Major topic |
| Dexamethasone | Major topic |
| gamma-Glutamyltransferase | Major topic |
| Anti-Inflammatory Agents | Major topic |
| Liver Cirrhosis | Major topic |
| Oligopeptides | Major topic |
| Animals | |
| Mice | |
| Hepatic Stellate Cells | |
| Humans | |
| Male | |
| Liver | |
| Mice, Inbred C57BL |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82403682 | the National Natural Science Foundation of China | PubMed | ||
| 82104365 | the National Natural Science Foundation of China | PubMed | ||
| 82274082 | the National Natural Science Foundation of China | PubMed | ||
| 100102 | Wellcome Trust | United Kingdom | PubMed | |
| 100102 | Wellcome Trust | United Kingdom | PubMed |
Source PubMed
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34864115 | Nano-designed CO donor ameliorates bleomycin-induced pulmonary fibrosis via macrophage manipulation. | J Control Release | 2022 | https://conductscience.org/library/papers/34864115 | PubMed |
| 2 | 40467841 | The spatial and temporal activation of macrophages during fibrosis. | Nat Rev Immunol | 2025 | https://conductscience.org/library/papers/40467841 | PubMed |
| 3 | 34136662 | Non-bonded force field model with advanced restrained electrostatic potential charges (RESP2). | Commun Chem | 2020 | https://conductscience.org/library/papers/34136662 | PubMed |
| 4 | 41034621 | Chitosan-encapsulated Aloe vera nanoparticles outperform carrier-free forms in enhancing MSCs therapy for amikacin nephrotoxicity. | Sci Rep | 2025 | https://conductscience.org/library/papers/41034621 | PubMed |
| 5 | 39864459 | Update in clinical science: Autoimmune hepatitis. | J Hepatol | 2025 | https://conductscience.org/library/papers/39864459 | PubMed |
| 6 | 32460113 | Self-assembling nanoparticles of dually hydrophobic prodrugs constructed from camptothecin analogue for cancer therapy. | Eur J Med Chem | 2020 | https://conductscience.org/library/papers/32460113 | PubMed |
| 7 | 24189300 | Protection of a new heptapeptide from Carapax trionycis against carbon tetrachloride-induced acute liver injury in mice. | Chem Pharm Bull (Tokyo) | 2013 | https://conductscience.org/library/papers/24189300 | PubMed |
| 8 | 37517452 | Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes. | J Hepatol | 2023 | https://conductscience.org/library/papers/37517452 | PubMed |
| 9 | 40535704 | Bioengineered platelet nanoplatform enables renal-targeted dexamethasone delivery for chronic nephritis therapy with dual anti-inflammatory/anti-fibrotic effects and minimized systemic toxicity. | Bioact Mater | 2025 | https://conductscience.org/library/papers/40535704 | PubMed |
| 10 | 37109344 | Baseline Predictors of the Long-Term Insufficient Biochemical Response in Patients with Autoimmune Hepatitis: A Single Center Experience. | J Clin Med | 2023 | https://conductscience.org/library/papers/37109344 | PubMed |
| 11 | 16200070 | Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. | Nat Immunol | 2005 | https://conductscience.org/library/papers/16200070 | PubMed |
| 12 | 33128017 | Molecular and cellular mechanisms of liver fibrosis and its regression. | Nat Rev Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/33128017 | PubMed |
| 13 | 33096584 | γ-Glutamyltranspeptidase (GGT)-Activatable Fluorescence Probe for Durable Tumor Imaging. | Angew Chem Int Ed Engl | 2021 | https://conductscience.org/library/papers/33096584 | PubMed |
| 14 | 39063116 | Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39063116 | PubMed |
| 15 | 18654426 | Nanocarriers as an emerging platform for cancer therapy. | Nat Nanotechnol | 2007 | https://conductscience.org/library/papers/18654426 | PubMed |
| 16 | 29727797 | Visualizing glioma margins by real-time tracking of γ-glutamyltranspeptidase activity. | Biomaterials | 2018 | https://conductscience.org/library/papers/29727797 | PubMed |
| 17 | 30285414 | Tandem Enzymatic Self-Assembly and Slow Release of Dexamethasone Enhances Its Antihepatic Fibrosis Effect. | ACS Nano | 2018 | https://conductscience.org/library/papers/30285414 | PubMed |
| 18 | 22070475 | Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. | N Engl J Med | 2011 | https://conductscience.org/library/papers/22070475 | PubMed |
| 19 | 24515270 | Liposomal oxymatrine in hepatic fibrosis treatment: formulation, in vitro and in vivo assessment. | AAPS PharmSciTech | 2014 | https://conductscience.org/library/papers/24515270 | PubMed |
| 20 | 29501581 | Oligo-peptide I-C-F-6 inhibits hepatic stellate cell activation and ameliorates CCl4-induced liver fibrosis by suppressing NF-κB signaling and Wnt/β-catenin signaling. | J Pharmacol Sci | 2018 | https://conductscience.org/library/papers/29501581 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| LOC102724197 | 102724197 | PubTator's text mining | https://conductscience.org/library/genes/102724197 | NCBI Gene |
| SMAD3 | 4088 | PubTator's text mining | https://conductscience.org/library/genes/4088 | NCBI Gene |
| STAT1 | 6772 | PubTator's text mining | https://conductscience.org/library/genes/6772 | NCBI Gene |
| TGFB1 | 7040 | PubTator's text mining | https://conductscience.org/library/genes/7040 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42226175
GET https://conductscience.org/api/papers/v1/42226175/references?page=2